Zhejiang Doer Biologics, a clinical stage biopharmaceutical startup in China developing innovative biotherapeutics for metabolic diseases and cancers, has entered into a license agreement with Germany-headquartered BioNTech SE. 

Under the terms of the agreement, Doer Bio will grant BioNTech a worldwide license to utilise one of Doer Bio's innovative discoveries to research, develop, manufacture, and commercialise innovative biotherapeutics against an undisclosed target.

Doer Bio will receive an upfront payment and will be eligible for potential development, regulatory, and commercial milestone payments.

"This license agreement with BioNTech is a great demonstration of the enormous potential of Doer Bio's platform technologies, which has been well validated by extensive preclinical research and ongoing clinical studies," said Yanshan Huang, Ph.D., founder and Chief Executive Officer of Doer Bio.

Powered by its proprietary xLONGylation, MultipleBody, AccuBody, and SMART-VHHBody technology platforms, the startup is developing innovative multi-domain based multi-specific therapeutic proteins. Doer Biologics' highly differentiated pipeline focuses on unmet clinical needs in the fields of cancer, endocrinology, metabolic diseases, and ophthalmology.